Aveo Capital Partners LLC Purchases 45,322 Shares of ARCA biopharma, Inc. (ABIO)
Aveo Capital Partners LLC boosted its stake in shares of ARCA biopharma, Inc. (NASDAQ:ABIO) by 93.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 93,667 shares of the biopharmaceutical company’s stock after buying an additional 45,322 shares during the period. Aveo Capital Partners LLC owned about 1.01% of ARCA biopharma worth $225,000 at the end of the most recent quarter.
ARCA biopharma, Inc. (NASDAQ:ABIO) opened at 1.825 on Wednesday. The firm’s market capitalization is $16.87 million. ARCA biopharma, Inc. has a 52 week low of $1.65 and a 52 week high of $3.12. The firm has a 50-day moving average of $2.35 and a 200 day moving average of $2.45.
ARCA biopharma (NASDAQ:ABIO) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter. Analysts predict that ARCA biopharma, Inc. will post ($1.75) earnings per share for the current year.
WARNING: “Aveo Capital Partners LLC Purchases 45,322 Shares of ARCA biopharma, Inc. (ABIO)” was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/09/aveo-capital-partners-llc-purchases-45322-shares-of-arca-biopharma-inc-abio.html.
About ARCA biopharma
ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).
Want to see what other hedge funds are holding ABIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARCA biopharma, Inc. (NASDAQ:ABIO).
Receive News & Ratings for ARCA biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.